FNDC5 and breast cancer: Although clinical trials directly testing irisin in patients with glioma are lacking, phase I trials in breast cancer (NCT04350463) show that recombinant irisin (100 μg/kg, biweekly IV) is well tolerated and reduces circulating IL-6.